<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497770</url>
  </required_header>
  <id_info>
    <org_study_id>10733</org_study_id>
    <secondary_id>H3E-US-B001</secondary_id>
    <nct_id>NCT00497770</nct_id>
  </id_info>
  <brief_title>An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed</brief_title>
  <official_title>Non-small Cell Lung Cancer: The Impact of Ethnic Origin on Patients Being Treated Second Line With Pemetrexed - An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This large, non-randomized observational study is being conducted to provide data about the
      impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of
      non-small cell lung cancer (NSCLC) in a routine medical care setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a large 1000 patient single arm observational study being conducted to determine the
      impact of ethnic origin (Caucasian, African-Americans, Asian-Americans, and Hispanics) on
      patients being treated for 2nd line advanced NSCLC with pemetrexed given in routine clinical
      practice. Data will be collected on disease control rate by pemetrexed as defined by Response
      Rate (RR) (Complete Response (CR) + Partial Response (PR)), Stable Disease (SD) and
      toxicities. In addition, overall survival, progression-free survival, treatment toxicities,
      activities of daily living, symptom burden and resource utilization will also be observed. To
      meet the study goals, a total of 400 Caucasians, 200 African- Americans, 200 Asian-Americans,
      and 200 Hispanics will be accrued to this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate)</measure>
    <time_frame>baseline to measured progressive disease (up to 20 cycles [14 months])</time_frame>
    <description>Disease Control Rate [DCR] is the percentage of participants with Complete Response (CR), Partial Response (PR), Stable Disease (SD), and SD or Incomplete Response (SI). Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; SD=small changes not meeting above criteria; SI=persistence of 1 or more non-target lesion(s) and/or maintenance of tumor marker level above normal limits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>baseline to date of death from any cause (up to 20 cycles [14 months])</time_frame>
    <description>Overall survival is the duration (months) from enrollment to death. For patients who are alive, overall survival is censored at the last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>baseline to measured progressive disease or death (up to 20 cycles [14 months])</time_frame>
    <description>Time from start of second line therapy until death, disease progression, or last contact expressed in months. Participants lost to follow-up (that were alive at last contact) were treated as censored using Kaplan-Meier survival analysis method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status Based on Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Plan and Prepare Meals</measure>
    <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
    <description>The daily activities assessed: ability to plan and prepare meals. OARS-IADL assesses the participant's ability to plan and prepare meals at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Drive or Use Public Transportation</measure>
    <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
    <description>The daily activities assessed: ability to drive or use public transportation. OARS-IADL assesses the participant's ability to drive or use public transportation at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Handle Personal Finances</measure>
    <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
    <description>The daily activities assessed: ability to handle personal finances. OARS-IADL assesses the participant's ability to handle personal finances at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Perform Housework Activities</measure>
    <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
    <description>The daily activities assessed: ability to perform housework activities. OARS-IADL assesses the participant's ability to perform housework activities at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Prepare and Take Medications</measure>
    <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
    <description>The daily activities assessed: ability to prepare and take medications. OARS-IADL assesses the participant's ability to prepare and take medications at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to do the Act of Shopping</measure>
    <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
    <description>The daily activities assessed: ability to do the act of shopping. OARS-IADL assesses the participant's ability to do the act of shopping at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Operate the Telephone</measure>
    <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
    <description>The daily activities assessed: ability to operate the telephone. OARS-IADL assesses the participant's ability to operate the telephone at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Score Associated With Treatment as Measured by the M.D. Anderson Symptom Inventory - LC(MDASI-LC)</measure>
    <time_frame>Baseline and end of treatment (up to 20 cycles [14 months])</time_frame>
    <description>The symptom score assessed: pain, fatigue, nausea, sleep, distress, shortness of breath, memory, appetite, drowsy, dry mouth, sadness, vomiting, numbness, cough, constipation, general activity, mood, work, relationships with other people, walking, enjoyment. Scores for each item range from 0 to 10, where 0 equaled no symptoms and 10 equaled worst possible symptoms. Assessed at baseline and end of treatment.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">434</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Caucasian</arm_group_label>
    <description>Caucasian patients receiving Alimta for 2nd line NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>African American</arm_group_label>
    <description>African American patients receiving Alimta for 2nd line NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asian American</arm_group_label>
    <description>Asian American patients receiving Alimta for 2nd line NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hispanic</arm_group_label>
    <description>Hispanic patients receiving Alimta for 2nd line NSCLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient</description>
    <arm_group_label>Caucasian</arm_group_label>
    <arm_group_label>African American</arm_group_label>
    <arm_group_label>Asian American</arm_group_label>
    <arm_group_label>Hispanic</arm_group_label>
    <other_name>LY231514</other_name>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving pemetrexed for second (2nd) line treatment of non-small cell lung cancer
        (NSCLC): 400 Caucasians, 200 African-Americans, 200 Asian-Americans, and 200 Hispanic
        patients will be accrued to this study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-small cell lung cancer (NSCLC) (any histologic type)

          -  Stage IIIB or IV disease

          -  Should have had 1 line of chemotherapy for Metastatic disease

          -  Adequate hematologic, hepatic and renal function

          -  Measurable or evaluable disease

        Exclusion Criteria:

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daly City</city>
        <state>California</state>
        <zip>94015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Cruz</city>
        <state>California</state>
        <zip>95065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33179</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kealakekua</city>
        <state>Hawaii</state>
        <zip>96750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morehead</city>
        <state>Kentucky</state>
        <zip>40351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Washington</city>
        <state>North Carolina</state>
        <zip>27889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78463</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monroe</city>
        <state>Washington</state>
        <zip>98272</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2007</study_first_submitted>
  <study_first_submitted_qc>July 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2007</study_first_posted>
  <results_first_submitted>March 15, 2012</results_first_submitted>
  <results_first_submitted_qc>March 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 11, 2012</results_first_posted>
  <last_update_submitted>April 27, 2012</last_update_submitted>
  <last_update_submitted_qc>April 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Target goals for recruitment were not met due to slow enrollment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Caucasian</title>
          <description>Caucasian participants receiving pemetrexed for second (2nd) line non-small cell lung cancer (NSCLC)</description>
        </group>
        <group group_id="P2">
          <title>African American</title>
          <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
        </group>
        <group group_id="P3">
          <title>Asian American</title>
          <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
        </group>
        <group group_id="P4">
          <title>Hispanic</title>
          <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Caucasian</title>
          <description>Caucasian participants receiving pemetrexed for second (2nd) line non-small cell lung cancer (NSCLC)</description>
        </group>
        <group group_id="B2">
          <title>African American</title>
          <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
        </group>
        <group group_id="B3">
          <title>Asian American</title>
          <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
        </group>
        <group group_id="B4">
          <title>Hispanic</title>
          <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="304"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="37"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="434"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.64" spread="9.94"/>
                    <measurement group_id="B2" value="62.74" spread="8.93"/>
                    <measurement group_id="B3" value="65.05" spread="11.31"/>
                    <measurement group_id="B4" value="63.14" spread="13.29"/>
                    <measurement group_id="B5" value="64.99" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Stage</title>
          <description>Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body). Stage IIIB - the cancer has spread to nearby tissue or spread to far away lymph nodes (locally advanced).
Stage IV - the cancer has spread to other organs of the body such as the other lung, brain, or liver (metastatic).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IIIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology of tumor</title>
          <description>This was an observational study, as such, the investigators followed the label recommendations and any changes to the label which occurred during the study, including but not limited to the tumor type.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other [not adenocarcinoma or squamous cell]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)</title>
          <description>Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 - Fully Active</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 - Ambulatory, Restricted Strenuous Activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - Ambulatory, No Work Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 - Partially Confined to Bed, Limited Self Care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Collected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate)</title>
        <description>Disease Control Rate [DCR] is the percentage of participants with Complete Response (CR), Partial Response (PR), Stable Disease (SD), and SD or Incomplete Response (SI). Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; SD=small changes not meeting above criteria; SI=persistence of 1 or more non-target lesion(s) and/or maintenance of tumor marker level above normal limits.</description>
        <time_frame>baseline to measured progressive disease (up to 20 cycles [14 months])</time_frame>
        <population>Of the 434 participants enrolled, 50 participants had a response status at the end of pemetrexed treatment indicating &quot;Not done/Missing&quot; and were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian</title>
            <description>Caucasian participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O2">
            <title>African American</title>
            <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O3">
            <title>Asian American</title>
            <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O4">
            <title>Hispanic</title>
            <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate)</title>
          <description>Disease Control Rate [DCR] is the percentage of participants with Complete Response (CR), Partial Response (PR), Stable Disease (SD), and SD or Incomplete Response (SI). Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; SD=small changes not meeting above criteria; SI=persistence of 1 or more non-target lesion(s) and/or maintenance of tumor marker level above normal limits.</description>
          <population>Of the 434 participants enrolled, 50 participants had a response status at the end of pemetrexed treatment indicating &quot;Not done/Missing&quot; and were not included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7"/>
                    <measurement group_id="O2" value="45.0"/>
                    <measurement group_id="O3" value="53.33"/>
                    <measurement group_id="O4" value="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A pre-specified logistic regression was used to assess non-inferiority of DCR in African American participants compared with Caucasian participants. The DCR for African Americans was to be considered non-inferior to the DCR for Caucasians if the upper bound of the confidence interval (CI) of the odds ratio (OR) for African American versus Caucasian was &lt;1.78 which corresponds to a difference in proportions of approximately 14% assuming the DCR in the reference group to be 50%.</non_inferiority_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.821</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.427</ci_lower_limit>
            <ci_upper_limit>1.580</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is the duration (months) from enrollment to death. For patients who are alive, overall survival is censored at the last contact.</description>
        <time_frame>baseline to date of death from any cause (up to 20 cycles [14 months])</time_frame>
        <population>All participants enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian</title>
            <description>Caucasian participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O2">
            <title>African American</title>
            <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O3">
            <title>Asian American</title>
            <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O4">
            <title>Hispanic</title>
            <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is the duration (months) from enrollment to death. For patients who are alive, overall survival is censored at the last contact.</description>
          <population>All participants enrolled in the study.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.77" spread="0.38" lower_limit="5.68" upper_limit="7.92"/>
                    <measurement group_id="O2" value="6.90" spread="1.34" lower_limit="4.53" upper_limit="8.94"/>
                    <measurement group_id="O3" value="16.0" spread="1.06" lower_limit="5.75" upper_limit="16.0"/>
                    <measurement group_id="O4" value="5.35" spread="0.91" lower_limit="2.04" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Time from start of second line therapy until death, disease progression, or last contact expressed in months. Participants lost to follow-up (that were alive at last contact) were treated as censored using Kaplan-Meier survival analysis method.</description>
        <time_frame>baseline to measured progressive disease or death (up to 20 cycles [14 months])</time_frame>
        <population>All participants enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian</title>
            <description>Caucasian participants receiving pemetrexed for second (2nd) line non-small cell lung cancer (NSCLC)</description>
          </group>
          <group group_id="O2">
            <title>African American</title>
            <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O3">
            <title>Asian American</title>
            <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O4">
            <title>Hispanic</title>
            <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Time from start of second line therapy until death, disease progression, or last contact expressed in months. Participants lost to follow-up (that were alive at last contact) were treated as censored using Kaplan-Meier survival analysis method.</description>
          <population>All participants enrolled in the study.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" lower_limit="2.40" upper_limit="3.35"/>
                    <measurement group_id="O2" value="2.99" lower_limit="2.33" upper_limit="4.73"/>
                    <measurement group_id="O3" value="5.08" lower_limit="2.50" upper_limit="11.1"/>
                    <measurement group_id="O4" value="2.20" lower_limit="1.81" upper_limit="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status Based on Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Plan and Prepare Meals</title>
        <description>The daily activities assessed: ability to plan and prepare meals. OARS-IADL assesses the participant's ability to plan and prepare meals at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
        <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
        <population>All participants enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian</title>
            <description>Caucasian participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O2">
            <title>African American</title>
            <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O3">
            <title>Asian American</title>
            <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O4">
            <title>Hispanic</title>
            <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status Based on Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Plan and Prepare Meals</title>
          <description>The daily activities assessed: ability to plan and prepare meals. OARS-IADL assesses the participant's ability to plan and prepare meals at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
          <population>All participants enrolled in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                    <measurement group_id="O2" value="63.1"/>
                    <measurement group_id="O3" value="70.3"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="13.5"/>
                    <measurement group_id="O4" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="10.8"/>
                    <measurement group_id="O4" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="26.2"/>
                    <measurement group_id="O3" value="37.8"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9"/>
                    <measurement group_id="O2" value="50.8"/>
                    <measurement group_id="O3" value="54.1"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Drive or Use Public Transportation</title>
        <description>The daily activities assessed: ability to drive or use public transportation. OARS-IADL assesses the participant's ability to drive or use public transportation at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
        <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
        <population>All participants enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian</title>
            <description>Caucasian participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O2">
            <title>African American</title>
            <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O3">
            <title>Asian American</title>
            <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O4">
            <title>Hispanic</title>
            <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Drive or Use Public Transportation</title>
          <description>The daily activities assessed: ability to drive or use public transportation. OARS-IADL assesses the participant's ability to drive or use public transportation at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
          <population>All participants enrolled in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2"/>
                    <measurement group_id="O2" value="63.1"/>
                    <measurement group_id="O3" value="62.2"/>
                    <measurement group_id="O4" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6"/>
                    <measurement group_id="O2" value="32.3"/>
                    <measurement group_id="O3" value="29.7"/>
                    <measurement group_id="O4" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="45.9"/>
                    <measurement group_id="O4" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9"/>
                    <measurement group_id="O2" value="50.8"/>
                    <measurement group_id="O3" value="54.1"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Handle Personal Finances</title>
        <description>The daily activities assessed: ability to handle personal finances. OARS-IADL assesses the participant's ability to handle personal finances at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
        <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
        <population>All participants enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian</title>
            <description>Caucasian participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O2">
            <title>African American</title>
            <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O3">
            <title>Asian American</title>
            <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O4">
            <title>Hispanic</title>
            <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Handle Personal Finances</title>
          <description>The daily activities assessed: ability to handle personal finances. OARS-IADL assesses the participant's ability to handle personal finances at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
          <population>All participants enrolled in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="67.7"/>
                    <measurement group_id="O3" value="83.8"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="26.2"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="6.2"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="45.9"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2"/>
                    <measurement group_id="O2" value="50.8"/>
                    <measurement group_id="O3" value="54.1"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Perform Housework Activities</title>
        <description>The daily activities assessed: ability to perform housework activities. OARS-IADL assesses the participant's ability to perform housework activities at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
        <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
        <population>All participants enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian</title>
            <description>Caucasian participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O2">
            <title>African American</title>
            <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O3">
            <title>Asian American</title>
            <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O4">
            <title>Hispanic</title>
            <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Perform Housework Activities</title>
          <description>The daily activities assessed: ability to perform housework activities. OARS-IADL assesses the participant's ability to perform housework activities at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
          <population>All participants enrolled in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1"/>
                    <measurement group_id="O2" value="44.6"/>
                    <measurement group_id="O3" value="54.1"/>
                    <measurement group_id="O4" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="33.8"/>
                    <measurement group_id="O3" value="32.4"/>
                    <measurement group_id="O4" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="16.9"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8"/>
                    <measurement group_id="O2" value="21.5"/>
                    <measurement group_id="O3" value="27.0"/>
                    <measurement group_id="O4" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="16.2"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                    <measurement group_id="O2" value="50.8"/>
                    <measurement group_id="O3" value="54.1"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Prepare and Take Medications</title>
        <description>The daily activities assessed: ability to prepare and take medications. OARS-IADL assesses the participant's ability to prepare and take medications at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
        <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
        <population>All participants enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian</title>
            <description>Caucasian participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O2">
            <title>African American</title>
            <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O3">
            <title>Asian American</title>
            <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O4">
            <title>Hispanic</title>
            <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Prepare and Take Medications</title>
          <description>The daily activities assessed: ability to prepare and take medications. OARS-IADL assesses the participant's ability to prepare and take medications at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
          <population>All participants enrolled in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="86.5"/>
                    <measurement group_id="O4" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="21.5"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9"/>
                    <measurement group_id="O2" value="36.9"/>
                    <measurement group_id="O3" value="45.9"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to do the Act of Shopping</title>
        <description>The daily activities assessed: ability to do the act of shopping. OARS-IADL assesses the participant's ability to do the act of shopping at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
        <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
        <population>All participants enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian</title>
            <description>Caucasian participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O2">
            <title>African American</title>
            <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O3">
            <title>Asian American</title>
            <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O4">
            <title>Hispanic</title>
            <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to do the Act of Shopping</title>
          <description>The daily activities assessed: ability to do the act of shopping. OARS-IADL assesses the participant's ability to do the act of shopping at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
          <population>All participants enrolled in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2"/>
                    <measurement group_id="O2" value="58.5"/>
                    <measurement group_id="O3" value="59.5"/>
                    <measurement group_id="O4" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="32.3"/>
                    <measurement group_id="O3" value="29.7"/>
                    <measurement group_id="O4" value="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1"/>
                    <measurement group_id="O2" value="24.6"/>
                    <measurement group_id="O3" value="40.5"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                    <measurement group_id="O2" value="21.5"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2"/>
                    <measurement group_id="O2" value="50.8"/>
                    <measurement group_id="O3" value="54.1"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Operate the Telephone</title>
        <description>The daily activities assessed: ability to operate the telephone. OARS-IADL assesses the participant's ability to operate the telephone at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
        <time_frame>beginning and at end of pemetrexed treatment (up to 20 cycles [14 months])</time_frame>
        <population>All participants enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian</title>
            <description>Caucasian participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O2">
            <title>African American</title>
            <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O3">
            <title>Asian American</title>
            <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O4">
            <title>Hispanic</title>
            <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Operate the Telephone</title>
          <description>The daily activities assessed: ability to operate the telephone. OARS-IADL assesses the participant's ability to operate the telephone at baseline and end of treatment. Responses: ability to do the activity without help, some help, unable, or not done (missing). The percent of participants responding in the different levels of functional ability are provided.</description>
          <population>All participants enrolled in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5"/>
                    <measurement group_id="O2" value="90.8"/>
                    <measurement group_id="O3" value="86.5"/>
                    <measurement group_id="O4" value="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="41.5"/>
                    <measurement group_id="O3" value="45.9"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some Help-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done (missing)-end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9"/>
                    <measurement group_id="O2" value="50.8"/>
                    <measurement group_id="O3" value="54.1"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Score Associated With Treatment as Measured by the M.D. Anderson Symptom Inventory - LC(MDASI-LC)</title>
        <description>The symptom score assessed: pain, fatigue, nausea, sleep, distress, shortness of breath, memory, appetite, drowsy, dry mouth, sadness, vomiting, numbness, cough, constipation, general activity, mood, work, relationships with other people, walking, enjoyment. Scores for each item range from 0 to 10, where 0 equaled no symptoms and 10 equaled worst possible symptoms. Assessed at baseline and end of treatment.</description>
        <time_frame>Baseline and end of treatment (up to 20 cycles [14 months])</time_frame>
        <population>The number of participants who had measurements for the subscale at those time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Caucasian</title>
            <description>Caucasian participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O2">
            <title>African American</title>
            <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O3">
            <title>Asian American</title>
            <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
          <group group_id="O4">
            <title>Hispanic</title>
            <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Score Associated With Treatment as Measured by the M.D. Anderson Symptom Inventory - LC(MDASI-LC)</title>
          <description>The symptom score assessed: pain, fatigue, nausea, sleep, distress, shortness of breath, memory, appetite, drowsy, dry mouth, sadness, vomiting, numbness, cough, constipation, general activity, mood, work, relationships with other people, walking, enjoyment. Scores for each item range from 0 to 10, where 0 equaled no symptoms and 10 equaled worst possible symptoms. Assessed at baseline and end of treatment.</description>
          <population>The number of participants who had measurements for the subscale at those time points.</population>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain-baseline (n=281, 62, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="3.27"/>
                    <measurement group_id="O2" value="3.73" spread="3.63"/>
                    <measurement group_id="O3" value="3.89" spread="3.32"/>
                    <measurement group_id="O4" value="3.75" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain-end of treatment (EOT) (n=118, 31, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.52" spread="3.25"/>
                    <measurement group_id="O2" value="5.16" spread="3.69"/>
                    <measurement group_id="O3" value="1.82" spread="2.30"/>
                    <measurement group_id="O4" value="1.88" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue-baseline (n=279, 62, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="2.83"/>
                    <measurement group_id="O2" value="4.58" spread="3.11"/>
                    <measurement group_id="O3" value="4.14" spread="2.37"/>
                    <measurement group_id="O4" value="5.04" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue-EOT (n=119, 32, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" spread="2.72"/>
                    <measurement group_id="O2" value="4.91" spread="3.30"/>
                    <measurement group_id="O3" value="3.71" spread="2.76"/>
                    <measurement group_id="O4" value="4.00" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea-baseline (n=280, 62, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="2.54"/>
                    <measurement group_id="O2" value="1.55" spread="2.60"/>
                    <measurement group_id="O3" value="1.34" spread="2.18"/>
                    <measurement group_id="O4" value="2.43" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea-EOT (n=118, 30, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="2.67"/>
                    <measurement group_id="O2" value="1.67" spread="2.66"/>
                    <measurement group_id="O3" value="1.18" spread="1.33"/>
                    <measurement group_id="O4" value="0.75" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep-baseline (n=280, 62, 34, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" spread="3.07"/>
                    <measurement group_id="O2" value="3.66" spread="3.59"/>
                    <measurement group_id="O3" value="3.21" spread="3.27"/>
                    <measurement group_id="O4" value="4.11" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep-EOT (n=118, 31, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="2.97"/>
                    <measurement group_id="O2" value="4.16" spread="3.40"/>
                    <measurement group_id="O3" value="2.94" spread="3.27"/>
                    <measurement group_id="O4" value="3.13" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distress (Upset)-baseline (n=277, 62, 34, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="3.01"/>
                    <measurement group_id="O2" value="3.00" spread="3.23"/>
                    <measurement group_id="O3" value="2.76" spread="2.71"/>
                    <measurement group_id="O4" value="4.07" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distress (Upset)-EOT (n=119, 32, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" spread="2.94"/>
                    <measurement group_id="O2" value="3.22" spread="3.58"/>
                    <measurement group_id="O3" value="2.41" spread="1.97"/>
                    <measurement group_id="O4" value="3.63" spread="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shortness of Breath-baseline (n=282, 61, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="3.06"/>
                    <measurement group_id="O2" value="3.70" spread="3.12"/>
                    <measurement group_id="O3" value="2.69" spread="3.00"/>
                    <measurement group_id="O4" value="4.29" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shortness of Breath-EOT (n=118, 32, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="3.12"/>
                    <measurement group_id="O2" value="5.06" spread="3.32"/>
                    <measurement group_id="O3" value="1.82" spread="2.53"/>
                    <measurement group_id="O4" value="2.88" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory-baseline (n=278, 62, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="2.56"/>
                    <measurement group_id="O2" value="2.71" spread="2.56"/>
                    <measurement group_id="O3" value="2.09" spread="2.31"/>
                    <measurement group_id="O4" value="2.50" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory-EOT (n=119, 32, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="2.56"/>
                    <measurement group_id="O2" value="2.81" spread="3.06"/>
                    <measurement group_id="O3" value="1.82" spread="2.38"/>
                    <measurement group_id="O4" value="0.63" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite-baseline (n=281, 62, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="3.02"/>
                    <measurement group_id="O2" value="3.11" spread="3.38"/>
                    <measurement group_id="O3" value="3.37" spread="2.73"/>
                    <measurement group_id="O4" value="4.86" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite-EOT (n=119, 32, 16, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="3.01"/>
                    <measurement group_id="O2" value="4.72" spread="4.03"/>
                    <measurement group_id="O3" value="2.38" spread="2.58"/>
                    <measurement group_id="O4" value="4.00" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsy-baseline (n=280, 65, 32, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="2.79"/>
                    <measurement group_id="O2" value="3.32" spread="2.97"/>
                    <measurement group_id="O3" value="2.63" spread="2.38"/>
                    <measurement group_id="O4" value="4.36" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsy-EOT (n=119, 32, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="2.84"/>
                    <measurement group_id="O2" value="3.69" spread="3.56"/>
                    <measurement group_id="O3" value="1.59" spread="1.84"/>
                    <measurement group_id="O4" value="3.13" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry Mouth-baseline (n=279, 62, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="2.98"/>
                    <measurement group_id="O2" value="2.73" spread="3.06"/>
                    <measurement group_id="O3" value="3.29" spread="3.19"/>
                    <measurement group_id="O4" value="3.36" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry Mouth-EOT (n=119, 32, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="2.99"/>
                    <measurement group_id="O2" value="2.44" spread="3.04"/>
                    <measurement group_id="O3" value="2.71" spread="2.78"/>
                    <measurement group_id="O4" value="2.25" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sadness-baseline (n=278, 61, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="2.81"/>
                    <measurement group_id="O2" value="2.57" spread="3.23"/>
                    <measurement group_id="O3" value="2.74" spread="2.81"/>
                    <measurement group_id="O4" value="4.32" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sadness-EOT (n=119, 32, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="2.83"/>
                    <measurement group_id="O2" value="2.81" spread="3.59"/>
                    <measurement group_id="O3" value="2.06" spread="2.08"/>
                    <measurement group_id="O4" value="3.88" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting-baseline (n=282, 62, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="1.85"/>
                    <measurement group_id="O2" value="0.97" spread="2.06"/>
                    <measurement group_id="O3" value="0.66" spread="1.35"/>
                    <measurement group_id="O4" value="1.25" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting-EOT (n=119, 32, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="1.49"/>
                    <measurement group_id="O2" value="1.06" spread="2.03"/>
                    <measurement group_id="O3" value="0.88" spread="2.03"/>
                    <measurement group_id="O4" value="0.13" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbness-baseline (n=280, 61, 33, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" spread="2.99"/>
                    <measurement group_id="O2" value="3.34" spread="3.26"/>
                    <measurement group_id="O3" value="2.76" spread="2.72"/>
                    <measurement group_id="O4" value="2.39" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbness-EOT (n=119, 32, 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="2.64"/>
                    <measurement group_id="O2" value="3.84" spread="3.47"/>
                    <measurement group_id="O3" value="2.47" spread="2.15"/>
                    <measurement group_id="O4" value="0.63" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough-baseline (n=281, 61, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="2.92"/>
                    <measurement group_id="O2" value="2.98" spread="2.91"/>
                    <measurement group_id="O3" value="2.63" spread="2.77"/>
                    <measurement group_id="O4" value="2.61" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough-EOT (n=119, 31, 16, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="2.63"/>
                    <measurement group_id="O2" value="3.94" spread="3.21"/>
                    <measurement group_id="O3" value="1.63" spread="1.96"/>
                    <measurement group_id="O4" value="3.13" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation-baseline (n=281, 62 34, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="3.11"/>
                    <measurement group_id="O2" value="2.37" spread="3.17"/>
                    <measurement group_id="O3" value="2.79" spread="3.22"/>
                    <measurement group_id="O4" value="3.54" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation-EOT (n=119, 32 17, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="2.85"/>
                    <measurement group_id="O2" value="2.88" spread="3.50"/>
                    <measurement group_id="O3" value="2.47" spread="3.10"/>
                    <measurement group_id="O4" value="1.50" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Activity-baseline (n=280, 62, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" spread="3.13"/>
                    <measurement group_id="O2" value="3.56" spread="3.38"/>
                    <measurement group_id="O3" value="2.46" spread="2.69"/>
                    <measurement group_id="O4" value="4.46" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Activity-EOT (n=119,32,16,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="3.04"/>
                    <measurement group_id="O2" value="4.53" spread="3.65"/>
                    <measurement group_id="O3" value="2.88" spread="2.70"/>
                    <measurement group_id="O4" value="3.63" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood-baseline (n=279, 61, 34, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="2.96"/>
                    <measurement group_id="O2" value="3.11" spread="3.07"/>
                    <measurement group_id="O3" value="2.44" spread="2.78"/>
                    <measurement group_id="O4" value="3.86" spread="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood-EOT (n=119, 32, 16, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="2.24"/>
                    <measurement group_id="O2" value="1.88" spread="2.23"/>
                    <measurement group_id="O3" value="1.89" spread="2.26"/>
                    <measurement group_id="O4" value="1.86" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work-baseline (n=278, 62, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="3.32"/>
                    <measurement group_id="O2" value="4.23" spread="3.86"/>
                    <measurement group_id="O3" value="2.51" spread="2.45"/>
                    <measurement group_id="O4" value="4.86" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work-EOT (n=118, 32, 16, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" spread="3.47"/>
                    <measurement group_id="O2" value="4.63" spread="3.72"/>
                    <measurement group_id="O3" value="2.81" spread="2.48"/>
                    <measurement group_id="O4" value="4.25" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationships with Others-baseline(n=282,61,35,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="2.53"/>
                    <measurement group_id="O2" value="2.41" spread="3.07"/>
                    <measurement group_id="O3" value="2.00" spread="2.52"/>
                    <measurement group_id="O4" value="3.07" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationships with Others-EOT (n=118, 31, 16, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="2.76"/>
                    <measurement group_id="O2" value="2.71" spread="3.13"/>
                    <measurement group_id="O3" value="1.50" spread="2.31"/>
                    <measurement group_id="O4" value="2.75" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking-baseline (n=280, 62, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" spread="3.15"/>
                    <measurement group_id="O2" value="4.00" spread="3.39"/>
                    <measurement group_id="O3" value="2.80" spread="2.75"/>
                    <measurement group_id="O4" value="4.21" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking-EOT (n=119, 32, 16, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="3.32"/>
                    <measurement group_id="O2" value="4.44" spread="3.56"/>
                    <measurement group_id="O3" value="2.94" spread="2.54"/>
                    <measurement group_id="O4" value="4.00" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment-baseline (n=282, 61, 35, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="3.26"/>
                    <measurement group_id="O2" value="3.51" spread="3.38"/>
                    <measurement group_id="O3" value="2.83" spread="2.81"/>
                    <measurement group_id="O4" value="4.39" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment-EOT (n=119, 32, 16, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="3.16"/>
                    <measurement group_id="O2" value="4.00" spread="3.77"/>
                    <measurement group_id="O3" value="2.81" spread="2.54"/>
                    <measurement group_id="O4" value="4.00" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Caucasian</title>
          <description>Caucasian participants receiving pemetrexed for second (2nd) line non-small cell lung cancer (NSCLC)</description>
        </group>
        <group group_id="E2">
          <title>African American</title>
          <description>African American participants receiving pemetrexed for 2nd line NSCLC</description>
        </group>
        <group group_id="E3">
          <title>Asian American</title>
          <description>Asian American participants receiving pemetrexed for 2nd line NSCLC</description>
        </group>
        <group group_id="E4">
          <title>Hispanic</title>
          <description>Hispanic participants receiving pemetrexed for 2nd line NSCLC</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="304"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="76" subjects_affected="55" subjects_at_risk="304"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="84" subjects_affected="55" subjects_at_risk="304"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="59" subjects_affected="45" subjects_at_risk="304"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="516" subjects_affected="242" subjects_at_risk="304"/>
                <counts group_id="E2" events="108" subjects_affected="52" subjects_at_risk="65"/>
                <counts group_id="E3" events="57" subjects_affected="27" subjects_at_risk="37"/>
                <counts group_id="E4" events="37" subjects_affected="21" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="304"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="79" subjects_affected="55" subjects_at_risk="304"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is an observational study, as such, the investigators followed the label recommendations and any changes to the label which occurred during the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>1-800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

